At #ESMO26, GI oncology experts are keeping their eye on key presentations in CRC and pancreatic cancer.

Sign up and read our preview of some of the top GI cancer abstracts to watch at the 2026 ESMO Congress in Madrid #crcsm #pancsm

www.onclive.com/view/targete...

Pancreatic cancer treatment is expanding in Japan: The MHLW has approved Optune Pax for concomitant use with gemcitabine and nab-paclitaxel in unresectable locally advanced disease #pancsm #oncology

www.onclive.com/view/optune-...

WATCH 🎥: Meredith Pelster, MD, MSCI, discusses the biomarker-agnostic design of the phase 3 MAPKeeper 301 trial of atebimetinib in metastatic pancreatic cancer. #pancsm #oncology

Full video ➡️: www.onclive.com/view/dr-pels...

🔬 Benjamin Weinberg, MD, discusses the @fda.gov approval of daraxonrasib, RASolute 302 survival data, safety considerations, and the future of RAS-targeted therapies in pancreatic cancer. #pancsm #oncology

Read more ➡️: www.onclive.com/view/daraxon...

WATCH: Philip A. Philip, MD, of @henryfordhealth.bsky.social, discusses how tumor treating fields work and their role in locally advanced pancreatic cancer following the Optune Pax @fda.gov approval. #pancsm #oncology

www.onclive.com/view/dr-phil...

🎙️On this episode of #OncLiveOnAir Philip A. Philip, MD, of @henryfordhealth.bsky.social discusses TTFields in pancreatic cancer and what phase 3 data has shown in locally advanced disease.

Listen here ➡️: www.onclive.com/view/explori...

#pancsm #oncology

An early-stage trial found encouraging outcomes with motixafortide, cemiplimab, gemcitabine, and nab-paclitaxel in newly diagnosed pancreatic cancer that had spread. @kenolivelab.bsky.social @columbiacancer.bsky.social #pancsm #oncology

Full story ➡️: www.onclive.com/view/a-new-c...

Dr. Eileen O’Reilly outlines a phase III trial of a targeted therapy for patients with metastatic pancreatic cancer. https://bit.ly/46A8VQD #OncSky #PanCSM

WATCH 🎥: Zev A. Wainberg, MD, of @uclahealth.org, discusses the phase 3 DAWN-303 trial of INCB161734 plus chemotherapy and the expanding role of KRAS inhibitors in pancreatic cancer. #pancsm #oncology

Full video here ➡️: www.onclive.com/view/dr-wain...

👀 "This was the third line of treatment for pancreatic cancer, which is typically a refractory population, [thus] a 37% ORR is quite significant," said @bhuffmanmd.bsky.social of @danafarber.bsky.social on phase 1 data for INCB161734

Read more here 📰: onclive.com/view/phase-1...

#pancsm #oncology

‼️ The @fda.gov has granted breakthrough therapy designation to daraxonrasib plus gemcitabine and nab-paclitaxel for treatment-naive mPDAC. #pancsm #oncology

See our site for the full story ➡️: www.onclive.com/view/fda-gra...